vs
Side-by-side financial comparison of Medicus Pharma Ltd. (MDCX) and ORAMED PHARMACEUTICALS INC. (ORMP). Click either name above to swap in a different company.
Oramed Pharmaceuticals Inc., is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
MDCX vs ORMP — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.6K | $0 |
| Net Profit | $-20.9M | $10.0M |
| Gross Margin | — | — |
| Operating Margin | -0.1% | — |
| Net Margin | -180917.3% | — |
| Revenue YoY | -79.2% | — |
| Net Profit YoY | -818.7% | 198.2% |
| EPS (diluted) | $-1.12 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $0 | ||
| Q3 25 | $11.6K | $0 | ||
| Q2 25 | $40.0K | $0 | ||
| Q1 25 | — | $2.0M | ||
| Q3 24 | $55.5K | — | ||
| Q4 23 | — | $0 | ||
| Q3 23 | — | $0 | ||
| Q2 23 | — | $674.0K |
| Q4 25 | — | $10.0M | ||
| Q3 25 | $-20.9M | $48.4M | ||
| Q2 25 | $-6.2M | $13.3M | ||
| Q1 25 | — | $-7.6M | ||
| Q3 24 | $-2.3M | — | ||
| Q4 23 | — | $12.9M | ||
| Q3 23 | — | $-3.2M | ||
| Q2 23 | — | $-1.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.7% | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -0.1% | — | ||
| Q2 25 | -15038.7% | — | ||
| Q1 25 | — | -225.0% | ||
| Q3 24 | -4204.8% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -562.5% |
| Q4 25 | — | — | ||
| Q3 25 | -180917.3% | — | ||
| Q2 25 | -15438.7% | — | ||
| Q1 25 | — | -382.1% | ||
| Q3 24 | -4104.8% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -177.2% |
| Q4 25 | — | $0.25 | ||
| Q3 25 | $-1.12 | $1.13 | ||
| Q2 25 | $-0.43 | $0.31 | ||
| Q1 25 | — | $-0.19 | ||
| Q3 24 | $-0.24 | — | ||
| Q4 23 | — | $0.33 | ||
| Q3 23 | — | $-0.08 | ||
| Q2 23 | — | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.7M | $51.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-910.1K | $199.7M |
| Total Assets | $10.0M | $230.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $51.4M | ||
| Q3 25 | $8.7M | $57.1M | ||
| Q2 25 | $9.7M | $17.6M | ||
| Q1 25 | — | $3.7M | ||
| Q3 24 | — | — | ||
| Q4 23 | — | $66.8M | ||
| Q3 23 | — | $49.4K | ||
| Q2 23 | — | $943.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | $74.5M | ||
| Q2 23 | — | — |
| Q4 25 | — | $199.7M | ||
| Q3 25 | $-910.1K | $203.3M | ||
| Q2 25 | $3.2M | $154.5M | ||
| Q1 25 | — | $140.8M | ||
| Q3 24 | $4.8M | — | ||
| Q4 23 | — | $163.8M | ||
| Q3 23 | — | $149.1M | ||
| Q2 23 | — | $151.5M |
| Q4 25 | — | $230.9M | ||
| Q3 25 | $10.0M | $220.5M | ||
| Q2 25 | $11.9M | $161.7M | ||
| Q1 25 | — | $147.5M | ||
| Q3 24 | — | — | ||
| Q4 23 | — | $220.6M | ||
| Q3 23 | — | $230.9M | ||
| Q2 23 | — | $156.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | 0.50× | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.8M | $-466.0K |
| Free Cash FlowOCF − Capex | — | $-468.0K |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.05× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-466.0K | ||
| Q3 25 | $-6.8M | $-1.6M | ||
| Q2 25 | $-5.5M | $-3.5M | ||
| Q1 25 | — | $-3.5M | ||
| Q3 24 | — | — | ||
| Q4 23 | — | $-1.4M | ||
| Q3 23 | — | $-694.0K | ||
| Q2 23 | — | $-2.6M |
| Q4 25 | — | $-468.0K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-3.5M | ||
| Q1 25 | — | $-3.5M | ||
| Q3 24 | — | — | ||
| Q4 23 | — | $-1.4M | ||
| Q3 23 | — | $-726.0K | ||
| Q2 23 | — | $-2.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -176.1% | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -393.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.1% | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 3.0% |
| Q4 25 | — | -0.05× | ||
| Q3 25 | — | -0.03× | ||
| Q2 25 | — | -0.27× | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q4 23 | — | -0.11× | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
